Search

中文 / English

Copyright: Shenzhen Kangtai biological products Limited by Share Ltd   Address: No. 6, KORUN Road, Nanshan District science and Technology Park, Shenzhen Tel:86-755-26988688
粤ICP备06026377号   Fax:86-755-26988600         E-mail:office@biokangtai.com        Hotline:400-880-6992    Powered by www.300.cn

>
development path
Page view:

1992

 

Company establishment

 

1995

5 μg/0.5ml/standard hepatitis B vaccine meets Merck's quality standards

 

 

Obtaining the Ministry of Health trial production approval number

 

1998

 

Obtained the official approval number from the State Food and Drug Administration

 

2000

 

Hepatitis B vaccine passed GMP certification for the first time

 

2002

 

Successfully Developed 10 μg/1.0ml/Standard Hepatitis B Vaccine for Adults

 

2004

 

Successfully developed the first three-year hepatitis B vaccine in China

 

2005

Add 10μg/0.5ml/piece of standard hepatitis B vaccine for adults, replacing 10μg/1.0ml/piece size

 

Hepatitis B vaccine passed GMP certification for the second time

 

2008

 

After the strategic reorganization, Beijing Minhai Biotechnology Co., Ltd. became a wholly-owned subsidiary of Kangtai Biotechnology

 

2010

First domestically developed 60μg/1.0ml/counter hepatitis B vaccine for adult non-response population

 

Hepatitis B vaccine passed GMP certification for the third time

2011

Successfully developed adult 20μg/1.0ml/support hepatitis B vaccine

 

Successfully developed 10g/0.5ml/standard hepatitis B vaccine for children

 

2012

Haemophilus influenzae type b conjugate vaccine passed GMP certification

 

Acellular Baidubai Haemophilus influenzae combined vaccine passed GMP certification

 

2013

 

Measles Rubella Combined with Live Attenuated Vaccine Passes GMP Certification

 

2014

Hepatitis B vaccine passed the 2010 version of GMP certification

 

Haemophilus influenzae type b conjugate vaccine (pre-filled) passed GMP certification

 

2017

The company is listed on the GEM of Shenzhen Stock Exchange, stock code 300601

2018 In October, Kangtai Guangming base was officially put into use
2019 23-Valent Pneumonia Vaccine received lot release and was officially launched into market
2020

Start construction of COVID-19 inactivated vaccine production workshop in Nanshan district,Shenzhen; 

Signs deal with AstraZeneca on development and industrialization of a COVID-19 vaccine based on adenovirus vector